Attovia Therapeutics, Inc. ATTO
- Market cap
- $829.5M
- P/E
- —
Follow ATTO
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | — | — |
Analyst estimates 2026–2028 Powerpack |
Low Price | ||
| — | — | — | — | — | — | — | — | — | — | High Price | |||
| — | — | — | — | — | — | — | — | — | 44 |
Employees
|
|||
| — | — | — | — | — | — | — | — | — | 0 |
Revenue/Emp
|
|||
| — | — | — | — | — | — | — | — | — | — | Revenue | |||
| — | — | — | — | — | — | — | — | — | — | Gross Margin | |||
| — | — | — | — | — | — | — | — | — | — | EBT | |||
| — | — | — | — | — | — | — | — | — | — | EBT Margin | |||
| — | — | — | — | — | — | — | — | — | 0 |
Net Income
|
|||
| — | — | — | — | — | — | — | — | — | — | Depreciation | |||
| — | — | — | — | — | — | — | — | — | — | Revenue/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Earnings/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Cash Flow/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Capex/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Free CF/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Book Value/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Shares | |||
| — | — | — | — | — | — | — | — | — | — | PE Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PS Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PB Ratio | |||
| — | — | — | — | — | — | — | — | — | — | EV/Sales | |||
| — | — | — | — | — | — | — | — | — | — | EV/FCF | |||
| — | — | — | — | — | — | — | — | — | — | Op' Cash Flow | |||
| — | — | — | — | — | — | — | — | — | — | Capex | |||
| — | — | — | — | — | — | — | — | — | — | FCF | |||
| — | — | — | — | — | — | — | — | — | — | Working Cap' | |||
| — | — | — | — | — | — | — | — | — | — | Total Debt | |||
| — | — | — | — | — | — | — | — | — | — | Net Debt | |||
| — | — | — | — | — | — | — | — | — | — | Sh' Equity | |||
| — | — | — | — | — | — | — | — | — | — | ROA | |||
| — | — | — | — | — | — | — | — | — | — | ROIC | |||
| — | — | — | — | — | — | — | — | — | — | ROE | |||
Attovia Therapeutics, Inc. (ATTO) Latest News
21 Sep
Attovia Therapeutics (ATTO) pulled back, closing at $21.30 as investors weigh immune-mediated disease programs against its weak balance sheet and current valuation. Near-term sentiment softened: 1-day -3.79%, 7-day -13.13%, 30-day +2.40%, YTD -2.74%. The stock trades about 98% below the $42.20 consensus target, raising questions of mispricing versus a cautious, fundamentals-aligned view. A negative equity base yields a skewed P/B around -6.7x, making price-to-book unreliable; a DCF cannot be produced due to insufficient data on future cash flows. Risks include potential clinical delays or disappointing readouts and annual losses while revenue sits near $1.8 million. The piece frames mixed sentiment and urges investors to test numbers against risk tolerance, and highlights related stock-screening ideas from Simply Wall St. Negative equity and uncertain future cash flows create valuation ambiguity, yielding only a moderate impact on sentiment and potential trajectory.
2 Sep
Attovia Therapeutics reported second quarter 2026 financial results and provided a corporate update. Quarterly financial results reporting can shift investor views on performance and prospects.
31 Aug
RBC identifies Attovia Therapeutics as a potential key player in immunology and inflammation. RBC endorsement signals moderate upside for Attovia in immunology and inflammation.
17 Aug
Attovia Therapeutics is a clinical-stage biotech developing treatments to stop chronic itch at its source. Company profile on itch therapy pipeline may moderately affect investor awareness and positioning.
6 Aug
Attovia Therapeutics closed its upsized initial public offering with full exercise of the underwriters’ option to purchase additional shares. Upsized IPO closure secures major capital to fund operations and pipeline advancement.
Attovia Therapeutics, a developer of therapeutics for immune mediated diseases, debuts on Nasdaq under ticker ATTO. Nasdaq debut grants Attovia Therapeutics greater market visibility and capital access that can alter its growth trajectory.
Attovia Therapeutics, developer of immune mediated disease therapeutics, debuts on Nasdaq under ticker ATTO. Nasdaq debut provides major capital access and visibility boosting long-term prospects.
4 Aug
Attovia Therapeutics priced its upsized initial public offering. Upsized IPO delivers major capital infusion and shifts company to public status with heightened investor visibility.